Blue­bird CFO re­signs as com­pa­ny faces bleak eco­nom­ic fu­ture

For blue­bird bio, the FDA’s ver­dict on its gene ther­a­pies — slat­ed for Au­gust and Sep­tem­ber, re­spec­tive­ly — could be a life-or-death de­ci­sion.

The biotech, once a high-fly­ing Wall Street dar­ling that rep­re­sent­ed a new, flashy breed of drug de­vel­op­ers, re­vealed to in­vestors in a quar­ter­ly fil­ing that its cash prob­lems “raise sub­stan­tial doubt re­gard­ing its abil­i­ty to con­tin­ue as a go­ing con­cern” in the com­ing year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER